October 20th, 2011, 11:07 AM
Membro del Comitato Consultivo, Editore e Direttore del Forum Italiano di FluTrackers
Join Date: Dec 2007
Location: Padua, Italy
MMWR Morb Mortal Wkly Rep. Carbapenem-Resistant Klebsiella pneumoniae Associated with a Long-Term--Care Facility --- West Virginia, 2009--2011
[Source: US Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, full text: (LINK
Morbidity and Mortality Weekly Report (MMWR)
Carbapenem-Resistant Klebsiella pneumoniae Associated with a Long-Term--Care Facility --- West Virginia, 2009--2011
Weekly - October 21, 2011 / 60(41);1418-1420
On January 27, 2011, a West Virginia county health department was notified of a cluster of carbapenem-resistant Klebsiella pneumoniae (CRKP) cases detected by a local hospital (hospital A). CRKP infections frequently are resistant to a majority of antimicrobial agents and have an increased risk for morbidity and mortality (1). The West Virginia Bureau for Public Health (WVBPH) conducted field investigations to identify all cases, characterize risk factors for infection, and abstract data for a matched case-control study. Nineteen case-patients and 38 control patients were identified. Infection with CRKP was associated with admission from or prior stay at a local long-term--care facility (LTCF A). Pulsed-field gel electrophoresis (PFGE) analysis indicated that all five hospital A clinical specimens and all 11 point prevalence survey isolates from LTCF A were closely related. This is the first outbreak of CRKP identified in West Virginia.
Recommendations to LTCF A included the following: 1) initiate surveillance for multidrug resistant organisms; 2) revise and improve infection prevention and control activities within the facility; 3) educate residents and their families, physicians, and staff members about CRKP; and 4) identify qualified personnel to coordinate infection control functions within the facility. Although LTCF A has made significant improvements, the outbreak investigation is ongoing. Additional site visits have been conducted, and additional colonized residents have been identified; the last clinical case was detected in July.
These findings demonstrate the interconnectedness of the health-care system and factors potentially contributing to transmission of infection. Interventions targeting all levels of care are needed to prevent further CRKP transmission.
In collaboration with the local health department and hospital A, WVBPH conducted an initial field investigation during February 7--9 to identify all cases and characterize infection risk factors. A case was defined as the first detection of CRKP in a patient admitted to a hospital A unit during April 2009--February 2011. Descriptive analysis was conducted to evaluate patient demographics, admitting hospital unit, reason for admission, admitting source for patient, and time between admission and collection of culture specimen.
A second field investigation was conducted during February 21--24 to complete data abstraction for a matched case-control study. Control patients were identified among patients admitted to a hospital A unit with a clinical culture of carbapenem-susceptible K. pneumoniae during April 2009--February 2011. Where possible, each case-patient was matched within 10 years of age with two control patients and by date of specimen collection within 14 days. Data regarding patient demographics, initial admission to hospital A, indwelling devices and procedures, history of multidrug-resistant organisms (MDROs), history of stays in hospital A and LTCFs, and comorbid medical conditions (reported as Charlson comorbidity index scores*) were collected for both case-patients and controls.
Site visits to hospital A and LTCF A were conducted during the initial field investigation. Surveillance data and practices and infection control policies and practices of both facilities were reviewed. A point prevalence survey to identify the baseline prevalence of CRKP was conducted according CDC's recommended protocol (2) in the oncology and medical/surgical units at hospital A and facilitywide at LTCF A.
Data from the field investigation and matched case-control study were analyzed using statistical software. Risk factors for CRKP were assessed by performing exact conditional logistic regression to calculate exact odds ratio (OR) estimates and 95% confidence intervals for dichotomous variables. Because of nonnormal distribution of continuous variables, median two-sample tests were used to estimate statistically significant differences between case-patients and control patients.
A total of 19 cases were identified with specimen collection dates of April 4, 2009--February 21, 2011. Among those cases, 16 patients had been admitted from LTCFs, 14 of whom were from LTCF A (…). Cultures were collected from 10 of the 14 LTCF A case-patients ≤2 calendar days after admission to hospital A, indicating they likely arrived at the hospital with infection.
A total of 38 control patients were identified. Multiple characteristics of case-patients and control patients were compared (…). Age, race, and Charlson comorbidity scores were similar for both groups, but case-patients (58%) were more likely than control patients (16%) to be male. Case-patients had a longer length of hospital stay (mean = 11.4 days) and a higher number of previous hospitalizations (mean = 2.5).
Because of the small number of case-patients, risk factors for CRKP infection (…) were evaluated by exact conditional logistic regression. Risk for CRKP infection was most strongly associated with a prior stay at LTCF A (OR = 46.6) and being admitted from LTCF A (OR = 35.1). Case-patients were significantly less likely than control patients to be ambulatory at the time of diagnosis and to have spent time at home during the previous year.
Hospital A surveillance and infection control practices were determined to be sufficient, whereas evaluation of surveillance and infection control practices at LTCF A revealed deficiencies. The infection preventionist position at LTCF A had been vacant for 9 months. An electronic surveillance system was available, but the facility did not record laboratory reports or MDRO status of residents in this system. LTCF A used a medical laboratory that does not report carbapenem resistance, and no record existed of CRKP infection among LTCF A residents. Staff hand hygiene stations were not conveniently located, and supplies (e.g., gloves, gowns, and waste containers) were missing for compliance with contact precautions. Point prevalence surveys were conducted; none of 29 hospital A patient samples were positive for CRKP, whereas 11 (9%) of 118 resident samples, including eight from residents with previously unrecognized CRKP colonization, were positive from LTCF A. Five clinical isolates from hospital A and 11 surveillance isolates from LTCF A's point prevalence survey were forwarded to CDC for confirmation and PFGE analysis. All 16 isolates were confirmed as carbapenemase (KPC)-producing K. pneumoniae and shared >88% similarity in their PFGE patterns.
Diana Gaviria, MD, Victoria Greenfield, Berkeley County Health Dept; Danae Bixler, MD, Carrie A. Thomas, PhD, Sherif M. Ibrahim, MD, West Virginia Bur for Public Health. Alex Kallen, MD, Brandi Limbago, PhD, Brandon Kitchel, MS, Div of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases; Tegwin K. Taylor, DVM, EIS Officer, CDC. Corresponding contributor: Tegwin K. Taylor, email@example.com, 304-356-4007.
This report describes the first outbreak of CRKP detected in West Virginia. CRKP is the most common carbapenem-resistant Enterobacteriaceae in the United States (1). CRKP spread has been driven by dissemination of Enterobacteriaceae producing the KPC enzyme, which confers resistance to all beta-lactam antimicrobials (3). Delaying further spread of these organisms, especially in areas where they remain uncommon, is a public health priority. Aggressive infection control interventions have been successful in reducing outbreaks of these organisms in acute care and long-term--care settings (4--6).
CRKP infections frequently are resistant to the majority of antimicrobial agents and are associated with increased morbidity and mortality (1). In one report, nearly half of 99 patients with CRKP infection died during hospitalization (7).
CRKP isolates from these patients were resistant to beta-lactams, fluoroquinolones, and sulfonamides, and the isolates demonstrated variable susceptibility to aminoglycosides, polymyxin B, tetracycline, and tigecycline, substantially limiting treatment options (7). CRKP infections resistant to all antimicrobial agents tested, including carbapenems, polymyxin B, and tigecycline, have been reported recently (8).
LTCFs can be a challenging setting for preventing spread of MDRO infections, including CRKP. LTCFs serve as permanent homes for their residents, making restrictions on residents' activities undesirable. In addition, LTCFs often have multiple-occupancy rooms, and residents often share common living areas, including bathrooms, which might facilitate MDRO transmission. In addition, lack of resources, including infection control expertise, often is a concern. LTCF residents typically have underlying health conditions and regular exposure to antimicrobial agents, both of which are risk factors for MDRO colonization and infection. LTCF residents frequently are transferred to acute care hospitals for higher levels of medical care, allowing ample opportunity for movement of an MDRO to these facilities.
Because of the interconnectedness of health-care facilities, successful control of MDROs often requires a regional approach. Local and state health departments are positioned to facilitate and coordinate prevention efforts across the continuum of health care, even in the absence of regulatory authority. In one example of a coordinated regional approach to MDRO control, facilities in a common region implemented active surveillance, enhanced infection control measures (e.g., barrier precautions and hand hygiene), provided staff education, and improved intrafacility communication regarding patients' MDRO status. This community was able to lower its vancomycin-resistant enterococci prevalence in health-care facilities from 2.2% to 0.5% during a 2-year period (9).
With only 19 case-patients, this study sample was small, which restricts the precision of results and the types of analyses that can be conducted for a matched case-control study. Data abstraction relied solely on information provided in Hospital A medical records. Therefore, data for individual case-patients might be inconsistent or missing. Residual confounding is a known limitation of case studies and might exist in this study.
In response to the outbreak, WVBPH recommended that LTCF A group residents with CRKP infection or colonization, use contact precautions during care, conduct active surveillance for CRKP with periodic point prevalence surveys, improve communication of MDRO status when transferring residents to other facilities, and monitor staff member compliance with hand hygiene and contact precautions. This outbreak demonstrated the crucial role that LTCFs can have in the ongoing CRKP spread and verified that local and state health departments are vital to the public health response to MDRO outbreaks.
* Additional information is available in Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000;36:453--71.
- CDC. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care settings. MMWR 2010;58:256--60.
- CDC. Laboratory protocol for detection of carbapenem-resistant or carbapenemase-producing, Klebsiella spp. and E. coli from rectal swabs. Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at http://www.cdc.gov/ncidod/dhqp/pdf/ar/klebsiella_or_ecoli.pdf . Accessed July 1, 2011.
- Kallen, A, Srinivasan, A. Current epidemiology of multidrug-resistant gram-negative bacilli in the United States. Infect Control Hosp Epidemiol 2010;31(Suppl 1):S51--4.
- Munoz-Price L, Hayden M, Lolans K, et al. Successful control of an outbreak of Klebsiella pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010;31:341--7.
- Gregory C, Llata E, Stine N, et al. Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect Control Hosp Epidemiol 2010;31:476--84.
- Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol 2010;31:620--6.
- Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099--106.
- Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009;49:271--4.
- Ostrowsky B, Trick W, Sohn A, et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001;334:1427--33.
G_MICHIELI (aka IRONOREHOPPER)
Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
HTML code is On
The reader is responsible for discerning the validity, factuality or implications of information posted here, be it fictional or based on real events. Moderators on this forum make every effort to review the material posted on this site however, it is not realistically possible for our staff to manually review each post.
The content of posts on this site, including but not limited to links to other web sites, are the expressed opinion of the original authors or posters and are not endorsed by, or representative of the opinions of, the owners or administration of this website. The posts on this website are the opinion of the specific author or poster and should not be construed as statements of advice or factual information.
Not all posts on this website are intended as truthful or factual assertion by their authors. NO posts on this website should be considered factual information on face value alone. Users are encouraged to USE DISCERNMENT and do their own follow up research while reading and posting on this website. FluTrackers.com Inc. reserves the right to make changes to, corrections and/or remove entirely at any time posts made on this website without notice. In addition, FluTrackers.com Inc. disclaims any and all liability for damages incurred directly or indirectly as a result of a post on this website.
This site is provided "as is" without warranty of any kind, either expressed or implied. You should not assume that this site is error-free or that it will be suitable for the particular purpose which you have in mind when using it. In no event shall FluTrackers.com Inc. be liable for any special, incidental, indirect or consequential damages of any kind, or any damages whatsoever, including, without limitation, those resulting from loss of use, data or profits, whether or not advised of the possibility of damage, and on any theory of liability, arising out of or in connection with the use or performance of this site or other documents which are referenced by or linked to this site.
Finally, FluTrackers.com Inc. reserves the right to delete, correct, or make changes to any post on this website without notice at any time for any reason.
Fair Use Notice:
This site may contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. Users may make such material available in an effort to advance awareness and understanding of issues relating to public health, civil rights, economics, individual rights, international affairs, liberty, science & technology, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C.Section 107, the material on this site is distributed to those who have expressed a prior interest in receiving the included information for research and educational purposes.
In accordance with industry accepted best practices we ask that users limit their copy / paste of copyrighted material to the relevant portions of the article you wish to discuss and no more than 1 paragraph, and in no case more than 50% of the source material provide a link back to the original article and provide your original comments / criticism in your post with the article. Please remember you are responsible for what you post on the internet and you could be sued by the original copyright holder if you do not honor these rules.
If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of "Fair Use" and legitimately infringes on yours or your clients copyright
we may be contacted concerning copyright matters at:
c/o Sharon Sanders
1676 Hibiscus Avenue
Winter Park, Florida 32789
In accordance with section 512 of the U.S. Copyright Act our contact information has been registered with the United States Copyright Office. "Safe Harbor" noticing procedures as outlined in the DMCA apply to this website concerning all 3rd party posts published herein.
If notice is given of an alleged copyright violation we will act expeditiously to remove or disable access to the material(s) in question.
All 3rd party material posted on this website is the copyright of the respective owners / authors. FluTrackers.com Inc. makes no claim of copyright on such material.
For more information please visit:
Please be aware any communications sent complaining about a post on this website may be posted publicly at the discretion of the administration.
FluTrackers Does Not Provide Any Medical Advice:
FluTrackers, Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster.
The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website.
By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
By using and/or accessing this site, either passively or actively, you are agreeing to all of the above conditions. Also, by using and/or accessing this site, either passively or actively, you agree to conduct all business and legal affairs related to this website in the jurisdiction of Flutrackers.com Inc. which is registered in Central Florida, USA.
These Disclaimers are subject to change at anytime.
Email the Webmaster with questions or comments about this site at firstname.lastname@example.org
All times are GMT -5. The time now is 08:58 PM.